Artemis Strategic Investment Corporation (ARTE)

PHOENIX, AZ / ACCESSWIRE / November 2, 2023 / Artemis Strategic Investment Corporation (the "Company") announced today that, in connection with the previously announced liquidation of the Company's trust account, approximately $10.75 per share (the "Redemption Amount") will be paid out to holders of shares of the Company's Class A common stock that were included in the units issued in the Company's initial public offering, after removal from the trust account of (i) $100,000 interest to pay dissolution expenses and (ii) taxes payable. The Redemption Amount is expected to be paid out within ten business days after October 26, 2023.

PHOENIX, AZ / ACCESSWIRE / October 30, 2023 / Artemis Strategic Investment Corporation (the "Company") announced today that the Company and Danam Health, Inc. have mutually agreed to terminate the Agreement and Plan of Merger between the parties, dated as of August 7, 2023 (as amended on September 7, 2023, the "Merger Agreement"), pursuant to Sections 7.1(a) and 7.2 thereof, effective as of October 26, 2023 (the "Termination"). Upon the effectiveness of the Termination, the Merger Agreement will be of no further force and effect, with the exception of the specified provisions in Section 7.2 of the Merger Agreement, which shall survive the termination of the Merger Agreement and remain in full force and effect in accordance with their respective terms.

PHOENIX, AZ / ACCESSWIRE / September 18, 2023 / Artemis Strategic Investment Corporation (NASDAQ:ARTE), a publicly traded special purpose acquisition company ("Artemis"), today announced the filing of its registration statement on Form S-4 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in connection with Artemis' business combination with Danam Health, Inc. ("Danam"), a health services technology and pharmaceutical distribution company pioneering a healthcare ecosystem model designed to bring efficiency to the prescription journey and promote medication compliance. The Registration Statement contains a preliminary proxy statement and prospectus of Artemis in connection with this previously announced business combination between Artemis and Danam (the "Transaction").

Danam Health, Inc. ("Danam") is a health services technology and pharmaceutical distribution company pioneering an ecosystem model designed to empower various stakeholders in the prescription journey and patient medication compliance aspects of healthcare. Founded by a consortium of top-tier pharma executives dedicated to improving the last mile of medication and healthcare delivery, Danam aims to achieve commercial success by utilizing advanced integrative technology to overcome both cost- and geography-related patient access barriers.